Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level685 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,087 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03783949 | European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer(EUDARIO) | completed | Phase 2 | 122 | Universitaire Ziekenhuizen KU LeuvenOTHER | 5 | Jun 11, 2025 | clinicaltrials |
| NCT01309230 | A Trial of FANG™ Vaccine for Participants With Ovarian Cancer | completed | Phase 2 | 39 | Gradalis, Inc.INDUSTRY | 1 | Jun 8, 2025 | clinicaltrials |
| NCT05044871 | Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer(BRIGHT) | completed | Phase 2 | 108 | Tongji HospitalOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06087289 | A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(KANDOVA) | completed | Phase 1 / Phase 2 | 18 | Novakand Pharma ABINDUSTRY | 3 | Jun 8, 2025 | clinicaltrials |
| NCT05567601 | Doxil/Caelyx BE Study | completed | Phase 1 | 36 | Baxter Healthcare CorporationINDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT05939440 | Interventions to Decrease Financial Toxicity(P-COC) | completed | N/A | 60 | University of Alabama at BirminghamOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT02713386 | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 147 | NRG OncologyOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT02470299 | Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients | completed | N/A | 21 | New Mexico Cancer Research AllianceOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT02672098 | Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer | completed | Phase 1 | 3 | Loma Linda UniversityOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT03508570 | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | completed | Phase 1 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT06977334 | IOTA Ultrasound Criteria and Serum CA 125 for Ovarian Malignancy Detection(IOTA-CA125) | completed | — | 64 | Maharajgunj Medical CampusOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT03784378 | Continued Access to RXDX-105 | completed | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT03054298 | CAR T Cells in Mesothelin Expressing Cancers | completed | Phase 1 | 65 | University of PennsylvaniaOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT03198286 | Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors | completed | N/A | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT05092763 | Prehabilitation During the Neoadjuvant Window of Opportunity in Older Women With Ovarian Cancer(FIT4SURGERY) | completed | N/A | 30 | Northwestern UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT01471483 | Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer | completed | — | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06613230 | Improved Early Diagnosis in Female Pelvic Cancer With OC Detect | completed | — | 490 | Region SkaneOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT00516724 | Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel | completed | Phase 1 | 189 | AstraZenecaINDUSTRY | 3 | Apr 11, 2025 | clinicaltrials |
| NCT06917469 | Use of New MolEcular MarkErs for a persoNalized Therapy in Ovarian Cancer-MEMENTO(MEMENTO) | completed | — | 140 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT00436254 | Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer | completed | Phase 1 | 66 | University of WashingtonOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT03353831 | Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer | completed | Phase 3 | 574 | AGO Research GmbHINDUSTRY | 12 | Apr 6, 2025 | clinicaltrials |
| NCT04188652 | Diagnosing Ovarian Cysts - the DOC Study | completed | — | 1,123 | Rigshospitalet, DenmarkOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT04917744 | Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors | completed | — | 5 | Mayo ClinicOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT04696276 | Implementing Enhanced Recovery After Surgery (ERAS) Pathways In Major Gynecologic Oncology Operations In Greece(ERAS) | completed | N/A | 101 | University of West AtticaOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06879353 | Comparison of Single-Dose Tranexamic Acid Vs. Placebo in Ovarian Cancer Surgery | completed | N/A | 372 | Sheikh Zayed Medical CollegeOTHER_GOV | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02489903 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | completed | Phase 2 | 139 | EpicentRx, Inc.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT03268382 | p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 | completed | Phase 2 | 36 | Aprea TherapeuticsINDUSTRY | 3 | Mar 17, 2025 | clinicaltrials |
| NCT03206047 | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04330040 | Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer(SOLI) | completed | Phase 4 | 202 | AstraZenecaINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT05697198 | PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine(PREFER) | completed | — | 1,429 | Labcorp Corporation of America Holdings, IncINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT06853730 | Regional Distribution Mapping of Lymph Node Metastasis in Epithelial Ovarian Cancer | completed | — | 654 | Xu HuishanOTHER | 0 | Mar 3, 2025 | clinicaltrials |
| NCT04517357 | A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients | completed | Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT01220154 | Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer | completed | Phase 1 | 9 | David O'MalleyOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT03552471 | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 1 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT02891824 | ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab(ATALANTE) | completed | Phase 3 | 614 | ARCAGY/ GINECO GROUPOTHER | 7 | Feb 11, 2025 | clinicaltrials |
| NCT04805333 | Phase 1 Dose Escalation of ArtemiCoffee | completed | Phase 1 | 13 | Frederick R. Ueland, M.D.OTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT00753545 | Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer | completed | Phase 2 | 265 | AstraZenecaINDUSTRY | 17 | Feb 3, 2025 | clinicaltrials |
| NCT04492007 | Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS)(PRISMS) | completed | N/A | 46 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT04406623 | Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer | completed | Phase 1 | 27 | Shattuck Labs, Inc.INDUSTRY | 1 | Jan 30, 2025 | clinicaltrials |
| NCT05887531 | Abdominopelvic Cancer Prehabilitation | completed | N/A | 66 | Universitat Jaume IOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06798610 | The Impact of the Inflammation Index on Predicting Postoperative Complications in Ovarian Cancer | completed | — | 228 | Sakarya UniversityOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05995860 | Study of a Rapid Triadic Communication Intention Elicitation Intervention to Improve Supportive Oncology Care Delivery(PRECursOr) | completed | N/A | 47 | Indiana UniversityOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT03154190 | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | completed | N/A | 128 | Stanford UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT05633836 | MicroFluO: FLUorescence-guided Surgery for Ovarian Cancer(MicroFluO) | completed | N/A | 3 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT03532139 | Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study) | completed | Phase 2 | 24 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT04703920 | Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | completed | Phase 1 | 26 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 23, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 11, 2025source: clinicaltrials